Litcius/Paper detail

Ixazomib-Lenalidomide-Dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma

Roman Hájek, Jiří Minařík, Jan Štraub, Luděk Pour, Alexandra Jungová, Jesús G. Berdeja, Mario Boccadoro, Lucie Brožová, Andrew Spencer, Frits van Rhee, Jorge Vela‐Ojeda, Michael A Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin Costello, Faith E. Davies, Vânia T. M. Hungria, Hans C. Lee, Xavier Leleu, Noemí Puig, Robert M. Rifkin, Evangelos Terpos, Saad Z. Usmani, Katja Weisel, Jeffrey A. Zonder, Magda Bařinová, Matyáš Kuhn, Jiří Šilar, Lenka Čápková, Kenny Gálvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimír Maisnar

2021Future Oncology21 citationsDOIOpen Access PDF

Abstract

NCT02761187 (ClinicalTrials.gov).

Topics & Concepts

LenalidomideIxazomibMedicineDexamethasoneMultiple myelomaOncologyRefractory (planetary science)Internal medicineThalidomideClinical PracticeCarfilzomibPhysical therapyPhysicsAstrobiologyMultiple Myeloma Research and TreatmentsResearch on Leishmaniasis StudiesProtein Degradation and Inhibitors
Ixazomib-Lenalidomide-Dexamethasone in Routine Clinical Practice: Effectiveness in Relapsed/refractory Multiple Myeloma | Litcius